Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 2

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 2
---
 Securities and Exchange Commission. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This proxy statement/prospectus shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. PRELIMINARY PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING OF APx ACQUISITION CORP. I AND PROSPECTUS FOR ORDINARY SHARES AND WARRANTS OF OMNIGENICSAI CORP SUBJECT TO COMPLETION, DATED July 18 , 2025 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING OF
SHAREHOLDERS OF APX ACQUISITION CORP. I PROSPECTUS FOR 6,332,556 ORDINARY SHARES,
17,574,991 WARRANTS TO PURCHASE ORDINARY SHARES, AND
17,574,991 ORDINARY SHARES UNDERLYING WARRANTS
OF OMNIGENICSAI CORP This proxy statement/prospectus relates to the transactions contemplated by the Business Combination Agreement, dated as of March 25, 2024 (as the same has been or may be amended, modified, supplemented or waived from time to time, the “Business Combination Agreement”), by and among APx Acquisition Corp. I (“APx”), OmnigenicsAI Corp, a Cayman Islands exempted company (the “Company”), Heritas Merger Sub Limited, a Cayman Islands exempted company and a direct wholly -ownedsubsidiary of the Company (“Merger Sub”) and MultiplAI Health Ltd, a private limited company formed under the laws of England and Wales (“MultiplAI”), pursuant to which, among other things, Merger Sub will merge with and into APx (with APx being the surviving company and a direct wholly -ownedsubsidiary of the Company) in exchange for shareholders and warrant holders of APx receiving merger consideration consisting of ordinary shares, par value $0.0001 per share, of the Company (“Company Shares”) and warrants to purchase Ordinary Shares (“Company Warrants”), respectively. On August 27, 2024, Heritas Ltd., MultiplAI and the MultiplAI Shareholders (with APx’s consent) terminated the amended and restated share purchase agreement dated March 13, 2024 among Heritas Ltd., the MultiplAI Shareholders signatories thereto and Multi